110-16-7
[1]Patent:WO2006/63762,2006,A1.Locationinpatent:Page/Pagecolumn15
[2]Patent:WO2006/63762,2006,A1.Locationinpatent:Page/Pagecolumn16
[3]Patent:WO2006/63762,2006,A1.Locationinpatent:Page/Pagecolumn16
110-16-7
[1]Patent:WO2006/63762,2006,A1.Locationinpatent:Page/Pagecolumn16
[1]Patent:US2001/16207,2001,A1
[1]ACSMedicinalChemistryLetters,2014,vol.5,p.501-505
Title: Pharmacokinetic benefits of 3,4-dimethoxy substitution of a phenyl ring and design of isosteres yielding orally available cathepsin K inhibitors.
Journal: Journal of medicinal chemistry 20121025
Title: (1R,2R)-N-(1-cyanocyclopropyl)-2-(6-methoxy-1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carbonyl)cyclohexanecarboxamide (AZD4996): a potent and highly selective cathepsin K inhibitor for the treatment of osteoarthritis.
Journal: Journal of medicinal chemistry 20120726
Title: Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib.
Journal: Journal of the American Academy of Dermatology 20120301
Title: Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys.
Journal: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20120101
Title: Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys.
Journal: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20111201
Title: The cathepsin K inhibitor AAE581 induces morphological changes in osteoclasts of treated patients.
Journal: Microscopy research and technique 20100701
Title: Emerging targets in osteoporosis disease modification.
Journal: Journal of medicinal chemistry 20100610
Title: Pharmacological inhibitors to identify roles of cathepsin K in cell-based studies: a comparison of available tools.
Journal: Biological chemistry 20090901
Title: A simple in vitro assay for assessing the reactivity of nitrile containing compounds.
Journal: Bioorganic & medicinal chemistry letters 20090215
Title: Cathepsin K inhibitors as treatment of bone metastasis.
Journal: Current opinion in supportive and palliative care 20080901
Title: Drug-induced morphea: report of a case induced by balicatib and review of the literature.
Journal: Journal of the American Academy of Dermatology 20080701
Title: The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
Journal: Bioorganic & medicinal chemistry letters 20080201
Title: Emerging roles of cysteine cathepsins in disease and their potential as drug targets.
Journal: Current pharmaceutical design 20070101
Title: Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K.
Journal: Journal of medicinal chemistry 20051201
Title: Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity.
Journal: Journal of medicinal chemistry 20051201
Title: Jerome C, et al. Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys. Osteoporos Int. 2012 Jan;23(1):339-49.
Title: Gauthier JY, et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett. 2008 Feb 1;18(3):923-8.
